Breaking news

Flo Health Secures $200M Investment From General Atlantic, Signaling A New Era In Femtech

In a landmark move for the femtech industry, Flo Health has secured a $200 million investment from General Atlantic, a leading global growth equity firm. This significant capital infusion marks a pivotal moment for the company, underscoring the growing recognition and potential of technology dedicated to women’s health.

Founded in 2015, Flo Health has swiftly risen to prominence with its innovative mobile application designed to track menstrual cycles, ovulation, and overall reproductive health. The app has garnered over 230 million downloads globally, making it a crucial tool for millions of women seeking to manage their health more effectively. This investment from General Atlantic is poised to propel Flo Health into its next phase of growth, enabling it to expand its product offerings and enhance its technological capabilities.

General Atlantic’s decision to invest such a substantial sum is indicative of the broader trends within the femtech sector. The femtech market, which includes a range of products and services aimed at improving women’s health, is projected to grow exponentially over the next decade. The increasing awareness of women’s health issues, coupled with advancements in technology, has created a fertile ground for innovation and investment. By backing Flo Health, General Atlantic is not only supporting a single company but also signalling confidence in the sector’s future.

Yaroslava Goncharova, CEO of Flo Health, expressed enthusiasm about the partnership with General Atlantic, stating, “This investment will allow us to accelerate our mission of improving the health and wellbeing of women globally. We are excited to leverage General Atlantic’s expertise and resources to further enhance our product and reach more women around the world.”

Flo Health’s success is rooted in its user-centric approach, leveraging data science and artificial intelligence to provide personalised health insights. The app’s features include symptom tracking, health predictions, and educational content, all designed to empower women with knowledge about their bodies. With the new funding, Flo Health plans to deepen its AI capabilities, enhance its user experience, and expand its educational content, ensuring it remains at the forefront of the femtech industry.

General Atlantic, known for its strategic investments in technology and healthcare, sees Flo Health as a strategic addition to its portfolio. Sandeep Naik, Managing Director and Head of India & Southeast Asia at General Atlantic, highlighted the potential for growth in the femtech space. “Flo Health is at the intersection of healthcare and technology, addressing a significant market need with its innovative solutions. We believe in the company’s vision and are committed to supporting its growth trajectory.”

The $200 million investment also reflects a broader shift in the investment landscape, where gender-specific health solutions are gaining traction among investors. The femtech sector, which has historically been underfunded, is now witnessing increased interest and funding, signalling a positive change in how women’s health is valued and supported.

Flo Health’s journey from a startup to a leading player in femtech exemplifies the transformative potential of technology in healthcare. With General Atlantic’s backing, the company is well-positioned to continue its upward trajectory, driving innovation and improving health outcomes for women worldwide. As Flo Health embarks on this new chapter, the femtech industry will undoubtedly be watching closely, anticipating the strides the company will make in advancing women’s health.

China’s Humanoid Robot Boom Faces A Bigger Question: Can These Machines Make Money?

Unitree’s $9 Billion Bet On The Future Of Robotics

China’s humanoid robotics industry is attracting huge investor interest, but as Unitree Robotics prepares for its public debut, questions are growing over whether its robots can move beyond impressive acrobatics and become commercially viable tools.

The Hangzhou-based startup priced its IPO at 150.8 yuan ($22.4) per share, raising $900 million and valuing the company at 61 billion yuan, or about $9 billion. The offering attracted record retail demand on Shanghai’s STAR Market, with the online tranche oversubscribed more than 5,000 times and a winning rate of just 0.018%. Strategic investors included AI startup DeepSeek.

A Unitree-linked pre-IPO perpetual contract was trading at roughly four times the IPO price on Friday, highlighting the speculative interest surrounding the company.

Unitree is known for robots capable of kung fu kicks, backflips and recovering from falls. Yet analysts question whether the technology is ready for large-scale commercial use. “For these humanoid robots, to be honest, they’re fascinating. They can dance and all that, but I’ve never seen them doing any real housework,” said Hao Hong, managing partner of Lotus Asset Management.

In its prospectus, Unitree warned that mass adoption could take longer than expected because robotic hands are still not precise or durable enough for sustained use.

From Acrobatic Robots To Commercial Machines

Even advanced humanoid robots can currently perform only a limited number of tasks and typically operate for a few hours before recharging, according to Dominik Pross, an equity analyst at VP Bank. Most models run for up to four hours, while robots also need to be trained for individual tasks.

“Robots have to be specifically trained for each and every task entrusted to them, even the simplest,” Pross said.

More robotics listings are expected, with Unitree rivals AgiBot and Leju Robotics seeking listings in Hong Kong and Shenzhen. LimX Dynamics founder Will Zhang said last month that “listing is a must.”

China’s Cost Advantage

China’s manufacturing scale has helped it establish a leading position in robotics. Wood Mackenzie expects the global humanoid robot fleet to surpass 10 million units by 2035, while China already accounts for more than 70% of global industrial robot installations and nearly 90% of humanoids deployed last year.

Average humanoid robot prices fell 93% between 2020 and 2025 to $58,000. Unitree’s flagship G1 costs $16,000, while SemiAnalysis estimates that the company has cut the price of its G1 EDU model by more than 45% to $27,300, while maintaining a 67% gross margin.

Falling prices and government support are attracting investment, but analysts say it will take time to prove that humanoid robots can generate strong returns. Unitree’s revenue more than quadrupled last year, although adjusted first-quarter profit fell more than 52% as research and development and marketing spending increased. Nearly three-quarters of its humanoid revenue in the first nine months of 2025 came from research and education, highlighting the gap between demonstrations and widespread commercial use.

“Unlike many early-stage robotics companies, the Unitree story is backed by real revenue growth,” said Jeff Ko, chief analyst at CoinEx. Still, he noted that its $9 billion valuation, at more than 200 times last year’s earnings, reflects significant speculative interest.

Geopolitical Risks

Unitree’s IPO momentum has continued despite growing pressure on Chinese robotics companies. The U.S. moved last month to ban imports of foreign-made humanoid and four-legged robots, potentially exposing Unitree, which generated about 13% of its revenue from the U.S. last year.

Access to Nvidia hardware and software is another risk, as Chinese robotics companies rely on the technology to power their systems. “Chinese robot producers are not yet in a position to do without Western components completely,” Pross said.

China’s control over rare earths used in robot actuators and motors could nevertheless give its manufacturers an advantage, according to Bernstein analyst Dien Wang.

The Bigger Robotics Opportunity

The potential market is attracting major players, including Tesla, whose CEO Elon Musk is expanding production plans for Optimus humanoid robots. At the same time, some researchers argue that the future of robotics will not be limited to humanoids: quadruped and purpose-built robots can be cheaper and more reliable for repetitive industrial tasks, while humanoids may be better suited to unpredictable environments.

For Unitree, the challenge is no longer proving that its robots can perform impressive tricks. It is proving that they can do enough useful work to justify a $9 billion valuation.

eCredo
The Future Forbes Realty Global Properties
Aretilaw firm
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter